|Day Low/High||77.03 / 79.18|
|52 Wk Low/High||62.88 / 100.13|
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
I am incrementally using buy-write option orders to add some shares to core holdings.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
It has been a better year for the Russell 2000 and the small-caps it represents.
It is all about perception, and here are strong names to pick up on market weakness.
I have not seen a bullish breakout from a large base pattern in a while.
Here's how BMRN's chart looks after its blistering gains.
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.
I think M&A activity will pick up markedly going forward across the industry.
I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.
The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
It's a wonder to me how split this market really is.
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.